These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 8624269)

  • 1. Metabolic effects of pamidronate in patients with metastatic bone disease.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    Br J Cancer; 1996 May; 73(9):1089-95. PubMed ID: 8624269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
    Body JJ; Dumon JC; Gineyts E; Delmas PD
    Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
    Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
    Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
    Glover D; Lipton A; Keller A; Miller AA; Browning S; Fram RJ; George S; Zelenakas K; Macerata RS; Seaman JJ
    Cancer; 1994 Dec; 74(11):2949-55. PubMed ID: 7525038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in calcium homoeostasis in patients undergoing liver transplantation: effects of a single infusion of pamidronate administered pre-operatively.
    Bishop NJ; Ninkovic M; Alexander GJ; Holmes SD; Milligan T; Price C; Compston JE
    Clin Sci (Lond); 1999 Aug; 97(2):157-63. PubMed ID: 10409470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose intravenous pamidronate for metastatic bone pain.
    Purohit OP; Anthony C; Radstone CR; Owen J; Coleman RE
    Br J Cancer; 1994 Sep; 70(3):554-8. PubMed ID: 8080746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pamidronate administration improves the secondary hyperparathyroidism due to "Bone Hunger Syndrome" in a patient with osteoblastic metastases from prostate cancer.
    Berruti A; Sperone P; Fasolis G; Torta M; Fontana D; Dogliotti L; Angeli A
    Prostate; 1997 Dec; 33(4):252-5. PubMed ID: 9397197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
    Body JJ; Dumon JC; Piccart M; Ford J
    J Bone Miner Res; 1995 Aug; 10(8):1191-6. PubMed ID: 8585422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.
    Vinholes JJ; Purohit OP; Abbey ME; Eastell R; Coleman RE
    Ann Oncol; 1997 Dec; 8(12):1243-50. PubMed ID: 9496390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.
    Jagdev SP; Purohit P; Heatley S; Herling C; Coleman RE
    Ann Oncol; 2001 Oct; 12(10):1433-8. PubMed ID: 11762816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
    Gutteridge DH; Retallack RW; Ward LC; Stuckey BG; Stewart GO; Prince RL; Kent GN; Bhagat CI; Price RI; Thompson RI; Nicholson GC
    Bone; 1996 Oct; 19(4):387-94. PubMed ID: 8894145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion.
    Landman JO; Papapoulos SE
    Osteoporos Int; 1995 Mar; 5(2):93-6. PubMed ID: 7599454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest.
    Watanabe Y; Ohshima H; Mizuno K; Sekiguchi C; Fukunaga M; Kohri K; Rittweger J; Felsenberg D; Matsumoto T; Nakamura T
    J Bone Miner Res; 2004 Nov; 19(11):1771-8. PubMed ID: 15476576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
    Coleman RE; Houston S; James I; Rodger A; Rubens RD; Leonard RC; Ford J
    Br J Cancer; 1992 May; 65(5):766-8. PubMed ID: 1586605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of pamidronate on biochemical markers of bone metabolism in osteoporosis--a placebo-controlled dose-finding study.
    Mallmin H; Ljunghall S; Larsson K; Lindh E
    Ups J Med Sci; 1991; 96(3):205-12. PubMed ID: 1810080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trial. Aredia Multinational Cooperative Group.
    Tyrrell CJ
    Ann Oncol; 1994; 5 Suppl 7():S37-40. PubMed ID: 7532992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.